Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Population Pharmacokinetics of Tranexamic Acid for Craniosynostosis Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients (age range 3 months to 6 years) undergoing craniosynostosis repair, fronto-orbital advancement surgery and cranial remodeling surgery (i.e. total cavernal remodeling surgery).~Exclusion Criteria:~* Preexisting hematological abnormality (defined as a positive history of bleeding disorder or a known diagnosis of a genetic or acquired bleeding disorder)~* Preexisting coagulation defect (defined as PT, PTT or INR \>1.5 times normal or a n pre-existing genetic or acquired coagulation defect))~* Preexisting hepatic, renal, vascular, ocular and/or metabolic disorder~* History of acetylsalicylate ingestion within the last 14 days.~* History of NSAIDs ingestion with 2 days of the scheduled surgery date

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- high dose TXA (Type: EXPERIMENTAL): High dose TXA is the intervention.~A higher dose of tranexamic acid will be given to this arm as follows:~50 mg/kg loading dose and 5 mg/kg/h infusion
- Low Dose TXA (Type: EXPERIMENTAL): Low dose TXA is the intervention.~A lower dose of TXa will be given as follows:~10 mg/kg loading dose and 5 mg/kg/h infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).